CN108794449B — 一种氘代富马酸沃诺拉赞代谢物的合成方法
Assigned to Guangdong HEC Pharmaceutical Co Ltd · Expires 2023-08-04 · 3y expired
What this patent protects
本发明涉及一种制备氘代沃诺拉赞代谢物的中间体5‑(2‑氟‑3,4,5,6‑四氘苯基)‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯‑3‑甲醛(V)的方法。同时，首次提供了一种氘代沃诺拉赞代谢物M‑I‑d 4 ,M‑II‑d 4 及M‑III‑d 4 的制备方法。该方法以Suzuki偶联反应为关键步骤先制备得到中间体5‑(2‑氟‑3,4,5,6‑四氘苯基)‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯‑3‑甲醛(V)，再通过中间体(V)转化成目标产物，具有成本低、收率高等优点，适合工业化生产。
USPTO Abstract
本发明涉及一种制备氘代沃诺拉赞代谢物的中间体5‑(2‑氟‑3,4,5,6‑四氘苯基)‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯‑3‑甲醛(V)的方法。同时，首次提供了一种氘代沃诺拉赞代谢物M‑I‑d 4 ,M‑II‑d 4 及M‑III‑d 4 的制备方法。该方法以Suzuki偶联反应为关键步骤先制备得到中间体5‑(2‑氟‑3,4,5,6‑四氘苯基)‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯‑3‑甲醛(V)，再通过中间体(V)转化成目标产物，具有成本低、收率高等优点，适合工业化生产。
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.